Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Home

Header Top Menu

  • News & Featured Stories
  • Media
  • Careers
  • Contact Us
  • Our Science

    Sub Menu 1

    • Pfizer in the UK
      • Our History
      • Pharmaceutical Sciences
      • Devices Centre of Excellence
      • Global Regulatory Affairs
      • Material Characterisation Team
      • Anti-Counterfeit Laboratory
    • Our Therapy Areas
      • Anti-Infectives
      • Inflammation and Immunology
      • Internal Medicine
      • Oncology
      • Rare Disease
      • Vaccines

    Sub Menu 2

    • Developing New Medicines
      • Clinical Trials
      • Pipeline
    • Research partnerships
      • ADDoPT
      • Innovative Target Exploration Network (ITEN)
      • INSPIRE Programme
      • Medical Research Council Collaboration
      • The Stratified Medicine Programme
      • Partnership with Regeneron for UK Biobank exome sequencing
    • Breakthroughs that change patients’ lives
    Hot Topic

    What is a Variant?

    What is a Variant
  • Products

    Sub Menu 4

    • Prescription medicines

    Sub Menu 5

    • Safety of Medicines
      • Medicines Regulation
      • Reporting Side Effects
      • Counterfeit Medicines
    Hot Topic

    How Does a Protease Inhibitor Work?

    Protease Inhibitor
  • Responsibility

    Sub Menu 7

    • Transparency
      • HCP & HCO Annual Disclosure Reports
      • Healthcare Organisation Grants
      • Research and Development Funding
      • Patient Organisation Funding and Support
    • Codes of Conduct
      • Gender Pay Gap Report
      • Environmental, Health and Safety Policy
      • Section 172 Statements
      • Pfizer UK Modern Slavery Statement
      • Pfizer UK Tax Strategy

    Sub Menu 8

    • Environmental Sustainability
      • Climate Action
      • Global Actions
      • Our Partnerships & Commitments
      • Sustainable Medicines
      • UK Actions
    • Insurance Details
    • Animal Welfare
    Hot Topic

    How Pfizer is Fighting Climate Change

    How Pfizer is Fighting Climate Change
  • UK Society

    Sub Menu 10

    • Social Investment
      • Volunteering and Fundraising
      • Medicines Donations
    • Raising Public Awareness
      • Change the Course
      • Pfizer Sponsors Science Museum Group's 'Cancer Revolution' Exhibition
      • Pfizer Sponsors the Superhero Series
      • Pfizer sponsors Science Museum exhibition 'Superbugs'
      • Pfizer at the British Science Festival
      • Turning Heads at Westminster

    Sub Menu 11

    • Science Education
      • Developing Science Talent
      • 'Superbugs Join The Fight' School Programme
      • Online Learning
        • Student Education Area
        • Teacher Resources
      • Community Lab
      • Career Talks
      • Lab in a Box
    • Pfizer Worldwide
      • Global Health Fellows
      • Global Aid and Emergency Relief
      • International Trachoma Initiative
    Hot Topic

    VacciNation: tackling health inequalities across England

    VacciNation report
  • UK Health System

    Sub Menu 16

    • Working with the NHS and other Healthcare Organisations
      • Collaborative Working
        • Collaborative Working Project between Lloyds Pharmacy and Pfizer Vaccines
        • Joint Working
      • Donations and Grants
        • Independent Medical Grants and Donations
        • Donations of Goods, Services and Benefit in Kind
        • Grants
        • Donations and Grants Enquiry Form
    • Working with Healthcare Professionals
      • FAQs: Working with Healthcare Professionals
      • Pharmacy
      • Healthcare Professionals Congress Sponsorship

    Sub Menu 17

    • Working with Patient Organisations
      • Patient Involvement in Research and Development
      • Our ongoing partnership with the UK Sepsis Trust
      • Partnering with the NIHR and young people on clinical research
    • Pfizer Healthcare Hub
      • Pfizer Healthcare Hub: 2018
      • Pfizer Healthcare Hub: 2017
      • Connect with the Hub
    Hot topic

    Putting patients at the heart of clinical trials

    Patients at heart of clinical trials
  • News & Featured Stories
  • Media
  • Careers

    Carrers

    • Search Current Vacancies
    • Apprenticeships
      • Apprenticeship Vacancies
    • Undergraduate Placements
      • Undergraduate Vacancies
    • Meet our people
    • UK Top Employer
    • How Pfizer is fostering meaningful growth for every colleague, everywhere
  • Contact Us
  • Footer links

    Footer mobile menu

    • Footer Menu
    • Footer menu
      • Contact Us
      • Cookie Policy
      • Terms of Use
      • Privacy Policy
      • Sitemap
    • Footer social item
      • Facebook
      • Twitter
      • Instagram
      • YouTube

Why putting patients at the heart of Pfizer UK’s clinical trials continues to be a priority

Why putting patients at the heart of Pfizer UK’s clinical trials continues to be a priority
News & Featured Stories/ Why putting patients at the heart of Pfizer UK’s clinical trials continues to be a priority
22/04/2022

Dr. Natalie Bohm
Medical Director of External Engagement, Pfizer UK

At Pfizer, we know that patients and caregivers are the experts in their conditions and it’s essential that we collaborate when designing and delivering clinical research.

 

When we partner with these experts, we listen to their insights, revising the way our clinical trials are run, and how trial-related documents are written to ensure that our research truly aligns with the needs of those living with conditions and is accessible for all.

As well as improving how patients experience research, co-designing clinical research with people living with conditions works towards improving recruitment and retention in later trials.1 With a greater patient focus, and therefore a more successful clinical trial, we can reduce the time to availability for life-changing medicines.

 

Patient insights are invaluable and are often revelations for researchers. Whether it’s revising informed consent documents to be better understood, or adapting research protocols, patients should be at the centre of shaping clinical trial design and delivery. When we engage with people living with conditions, their knowledge and experience enable us to make changes that have a positive impact. We need to engage with a diverse range of patient groups to enable people from all demographics and communities to have a voice in impacting clinical research."

In our work we partner with many different types of organisations, including patient groups and the National Institute of Health Research (NIHR) – a government organisation that funds and delivers research into health and care – to ensure patients are at the heart of clinical research and trial co-design.

We have a long-standing relationship with the NIHR,2 and in 2018 we collaborated on a new project when the NIHR piloted its Patient Engagement in Clinical Development Service. This new service connects life science companies with adult and paediatric patients who want to help shape clinical research.3

The NIHR connected Pfizer with GenerationR, a Young People’s Advisory Group (YPAG) based in Liverpool. Researchers collaborate with YPAGs like GenerationR to gather young people’s opinions to inform clinical research design and delivery.

Our researchers gained fascinating insights from those involved which resulted in real improvements in the design of our clinical trials and revisions to informed consent documentation. This really illustrated the importance of involving young people. Adit Bassi was part of GenerationR and says, "This was such a fantastic opportunity where researchers understood the benefits of listening to young people’s insights and experiences. YPAGs and patient groups are ready to continue collaborating, and the more people that are involved, the greater the healthcare improvements and outcomes. Young people want to help shape clinical research for future generations and partnering with researchers is a perfect way to do this.’"

Since the conception and completion of this pilot project, Pfizer has worked with the NIHR on 15 separate patient engagement partnerships. The partnership has been so successful that the Patient Engagement in Clinical Development Service was recently shortlisted for the ‘Most Valuable Collaboration’ award at Reuters’ Pharma Awards Europe 2020,4 a reflection of how we engage with patient communities in meaningful and managed ways.

In all clinical trials where Pfizer has partnered with UK patients through the NIHR, changes were made to the design, documentation, or delivery as a direct result of engagement. We’re proud of our existing partnerships and are continuing to expand our engagements across different stages of the medicines development cycle.

By placing patients at the heart of clinical trials we can improve medicines development. At Pfizer we will continue to prioritise this invaluable insight, building on our successful engagement activities to ensure UK patients and caregivers of all ages and from all backgrounds are involved in the design and delivery of clinical research.

 

References

  1. NIHR. The balancing act: How patient engagement can improve recruitment and retention Accessed Feb 2022.
  2. Pharma Times. Pfizer teams up with NIHR Accessed Feb 2022.
  3. NIHR. Translating intention into action – Piloting the NIHR Patient Engagement in Clinical Development Service Accessed Feb 2022.
  4. Reuters Events. Pharma Awards Europe 2020 Accessed Feb 2022.

 

PP-INT-GBR-0540 / February 2022

Related Hot Topics
Patient View 2021
Pfizer UK ranked first for overall corporate reputation by PatientView Survey…
AMR Reimbursement Pilot Launch
World First Cross-Industry Initiative Launches in the Continued Fight Against…
What is a Variant
What is a Variant?
VacciNation report
VacciNation: tackling health inequalities across England
AMR Explained
Antimicrobial Resistance Explained
Infection Management Coalition Paper
Cross-Industry Coalition Tackling ‘Hidden Pandemic’ of Antibiotic Resistant…
Maternal Immunisation
Protecting Babies from Inside the Womb
Blueprint for gene therapy adoption
Pfizer UK launch blueprint for the UK adoption of cell and gene therapies
Tags
Science / R&D
UK Health System

Footer

  • Contact Us
  • Cookie Policy
  • Terms of Use
  • Privacy Policy
  • Sitemap

Footer aside

  • Footer Aside
    • Facebook
    • Twitter
    • Instagram
    • YouTube

Copyright © 2017-2022 Pfizer Limited. PP-PFE-GBR-4248 / Nov 2021. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427